First Study Evaluating the WATS3D Biopsy for the Detection of Biliary Tract Cancer
Two Studies Reinforcing the Value of WATS3D for Surveillance of Esophageal Pre-Cancer
SUFFERN, NY–(Marketwired – Oct 10, 2013) – CDx Diagnostics today announced that important new WATS3D (Wide Area Transepithelial Sample) clinical data will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting and Postgraduate Course, taking place from October 11-16, 2013 in San Diego. New WATS3D studies and scientific presentations at the meeting include:
The first study evaluating WATS3D for detecting cancer of the biliary tract
Two studies that add to the large evidence base supporting using WATS3D to monitor patients who have received ablation therapy for esophageal pre-cancer
A hands-on workshop presentation that will provide an overview of the WATS3D technology
The WATS3D biopsy collects a wide area, disaggregated tissue specimen of the entire thickness of the suspect epithelium. This unique tissue specimen is then subjected to specialized, computer-assisted 3-dimensional analysis to pinpoint potentially abnormal cells for presentation to a pathologist. In clinical trials, adjunctive use of WATS3D significantly increased the detection rate of both Barrett’s esophagus and esophageal dysplasia. ACG attendees can visit booth # 331 to learn more about WATS3D.
“Early detection is the key to preventing cancers of the esophagus and biliary tract, but the current diagnostic tools available to gastroenterologists have serious limitations,” said Mark Rutenberg, Chairman and CEO of CDx Diagnostics. “WATS3D addresses this urgent unmet need by enhancing the detection of pre-cancer missed by standard methods. Since the product was introduced last year, we have seen rapid uptake and the new data being presented at ACG should help to educate the gastroenterology community about the benefits of integrating WATS3D into clinical practice.”
Schedule of WATS3D studies and scientific presentations at ACG
Sunday, October 13, 3:30 PM – 7:00 PM
WATS3D at the Advanced Imaging & Diagnostics Hands-On Workshop
Seth Gross, MD, NYU Langone Medical Center
Poster P97: “Wide Area Transepithelial Sample 3-Dimensional Biopsy Brush with Computer-Assisted Analysis (WATS3D) during ERCP Improves Detection of Biliary Tract Malignancy”
Sang H. Kim, MD, Wallace J. Wang, MD, Moshe Rubin, MD, Konika P. Bose, MD, Anthony J. Nici, MD, Syed A. Hussain, MD, New York Hospital Queens/Weill Cornell Medical College
Poster P23: “Wide Area Transepithelial Sampling (WATS3D) Improves Detection of Residual or Recurrent Intestinal Metaplasia within the Tubular Esophagus and Squamocolumnar Junction”
Rahul D. Kataria, MD, Deena Midani, MD, Rebecca M. Thomas, MD, Michael S. Smith, MD, Temple University School of Medicine
Tuesday, Oct 15, 10:30 AM – 4:00 PM
Poster P1198: “Wide-area Transepithelial Sampling (WATS3D) Brush Biopsy as an Adjunct to Forceps Biopsy for the Detection of Barrett’s Metaplasia and Dysplasia after Endoscopic Therapy”
Danielle Marino, MD, Donald N. Tsynman, MD, Vivek Kaul, MD, University of Rochester Medical Center
About CDx Diagnostics and the WATS3D Biopsy
CDx Diagnostics’ mission is to provide doctors with the most powerful diagnostic technology to help prevent cancer before it can start.
CDx Diagnostics’ WATS3D biopsy addresses the sampling error inherent in random forceps biopsy testing of the esophagus. In just a few minutes, gastroenterologists can easily obtain a wide area, full-thickness transepithelial tissue sample for computer-assisted 3D laboratory analysis. In clinical trials, adjunctive use of CDx Diagnostics’ WATS3D biopsy significantly increased the detection rate of both Barrett’s esophagus and esophageal dysplasia. The high sensitivity of WATS3D is due to the large tissue area sampled, and the proprietary 3-Dimensionial computer imaging system that is based on an algorithm developed as part of the U.S. Strategic Defense Initiative missile defense program. To learn more about WATS3D, visit www.cdxdiagnostics.com.